Abstract A044: Mutated NPM1 as target for immunotherapy of acute myeloid leukemia
Dyantha I. van der Lee(Leiden University Medical Center), Marieke Griffioen(Leiden University Medical Center), Peter A. van Veelen(Leiden University Medical Center), Arnoud H. de Ru(Leiden University Medical Center), Mirjam M. Heemskerk(Leiden University Medical Center), Christiaan Kweekel, J.H. Frederik Falkenburg(Leiden University Medical Center), Dirk M. van der Steen, Hendrik Veelken(University of Freiburg), Michel G.D. Kester(Leiden University Medical Center), Inge Jedema(The Netherlands Cancer Institute), Renate S. Hagedoorn(Leiden University Medical Center), Rogier M. Reijmers(Amsterdam UMC Location Vrije Universiteit Amsterdam), M. Willy Honders(Leiden University Medical Center), Rob. M. de Jong(Leiden University Medical Center)
Cited by 0
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
|Bone Marrow Transplantation|2015|337
Essential role of stromally induced hedgehog signaling in B-cell malignancies
|Nature Medicine|2007|321
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
|Journal of Clinical Investigation|2019|232
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
|Bone Marrow Transplantation|2015|205